Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 14, 2018

SELL
$1.82 - $2.56 $106,961 - $150,451
-58,770 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$1.77 - $2.28 $497,481 - $640,823
-281,063 Reduced 82.71%
58,770 $115,000
Q1 2018

May 15, 2018

SELL
$1.77 - $4.39 $632,010 - $1.57 Million
-357,068 Reduced 51.24%
339,833 $618,000
Q4 2017

Feb 14, 2018

BUY
$4.08 - $7.4 $816,000 - $1.48 Million
200,000 Added 40.25%
696,901 $3.02 Million
Q3 2017

Nov 14, 2017

BUY
$3.42 - $8.74 $1.7 Million - $4.34 Million
496,901
496,901 $3.05 Million

About Akari Therapeutics Plc


  • Ticker AKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,349,200
  • Market Cap $145M
  • Description
  • Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...
More about AKTX
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.